In recent years IDL Biotech has been working on developing a rapid test to detect lung cancer, under the project name MonoTotal® Rapid. However, further development will instead focus on creating a rapid test for breast cancer.
Read the article here (Swedish)
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q4’25 results – February 26, 2026 Q4 Interview: Redeye talks with CEO Anders Hultman
Last week, IDL Diagnostics participated as an exhibitor at WHX Labs Dubai together with concile as part of the recently announced joint venture. The main focus is on delivering multiple biomarkers across different POC reader configurations and supporting infection,...
We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.
